Sitimagene ceradenovec

Drug Profile

Sitimagene ceradenovec

Alternative Names: Cerepro; EG009

Latest Information Update: 16 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ark Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; Thymidine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • Available For Licensing Yes - Glioma

Highest Development Phases

  • Discontinued Glioma

Most Recent Events

  • 05 May 2010 Sitimagene ceradenovec is available for licensing worldwide (
  • 05 Jan 2010 Ark Therapeutics files formal request with the EMEA for re-examination of MAA for sitimagene ceradenovec in operable malignant Glioma
  • 18 Dec 2009 CHMP adopts negative opinion of sitimagene ceradenovec in operable malignant Glioma in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top